Dudediligence.

Scienture Holdings, Inc

SCNXNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$64,861Sep ’24$53,083Dec ’24$10,258Mar ’25$590,050Sep ’25−$168,699Dec ’25$56,325Mar ’26$343,639Jun ’26
Net income, by quarter
−$3.2MSep ’24−$7.2MDec ’24−$3.1MMar ’25−$6.7MJun ’25−$3.6MSep ’25−$28.1MDec ’25−$3.4MMar ’26−$2.8MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$9.9M$10.3M$1.4M$136,643$431,609
Gross profit$4.7M$5.5M$49,030$6,005$331,482
Operating income−$5.3M−$2.9M−$4.4M−$14.7M−$42.6M
Net income−$5.3M−$3.5M−$17.8M$9.1M−$41.5M
Operating cash flow−$2.6M−$1.5M−$2.2M−$14.3M−$13.4M
Free cash flow−$2.6Mnone on filenone on file−$14.3Mnone on file
Cash$3.1M$1.1M$151,908none on file$6.7M
Debtnone on filenone on filenone on file$2.9Mnone on file
Shares outstanding8.2M626.2K905.0K8.8M40.6M